ASX:RAC

Race Oncology Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume76,322 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive RAC News and Ratings via Email

Sign-up to receive the latest news and ratings for Race Oncology and its competitors with MarketBeat's FREE daily newsletter.


About Race Oncology

Race Oncology Limited operates as a specialty pharmaceutical company in Australia. The company is developing Bisantrene, a small molecule cancer chemotherapy drug that is used for the treatment of acute myeloid leukaemia. It has a preclinical research program with the University of Newcastle to explore the use of Bisantrene to treat melanoma. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.21 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Race Oncology (ASX:RAC) Frequently Asked Questions

What stocks does MarketBeat like better than Race Oncology?

Wall Street analysts have given Race Oncology a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Race Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Race Oncology's earnings last quarter?

Race Oncology Limited (ASX:RAC) announced its quarterly earnings results on Wednesday, February, 27th. The company reported ($0.03) EPS for the quarter.
View Race Oncology's earnings history
.

Who are Race Oncology's key executives?

Race Oncology's management team includes the following people:
  • Mr. Phillip R. Lynch, CEO, MD & Director
  • Dr. Daniel Tillett, Chief Scientific Officer & Exec. Director
  • Prof. Borje S. Andersson, Chairman of Clinical Advisory Board & Chief Medical Officer
  • Mr. Peter Gordon Webse M.A.I.C.D., B.Bus, FGIA, FCIS, FCPA, MAICD, Company Sec. (Age 58)

Who are some of Race Oncology's key competitors?

What other stocks do shareholders of Race Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Race Oncology investors own include Mesoblast (MESO), Pilbara Minerals (PLS) and Mount Gibson Iron (MGX).

What is Race Oncology's stock symbol?

Race Oncology trades on the ASX under the ticker symbol "RAC."

How much money does Race Oncology make?

Race Oncology has a market capitalization of $0.00 and generates $387,385.00 in revenue each year.

What is Race Oncology's official website?

The official website for Race Oncology is www.raceoncology.com.

How can I contact Race Oncology?

The company can be reached via phone at 61 3 9097 1656.


This page was last updated on 9/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.